Media-OutReach Newswire GangaGen Secures additional US$7.9 Million from CARB-X for Pre-clinical Development of Novel Klebicins Targeting Nosocomial Pneumonia caused by Multidrug-resistant Klebsiella pneumoniae
Media-OutReach Newswire AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth points for performance
Opinion Amplifying the leadership of persons with disabilities for an inclusive and sustainable future